Ironwood医药（IRWD）今日盘前股价大涨28.5%，表现极为亮眼。
消息面上，Ironwood医药发布的2026年营收展望高于华尔街预期，主要得益于其与艾伯维公司（ABBV）联合销售的肠道疾病治疗药物Linzess的净销售额预计将显著上升。公司预计2026年Linzess的净销售额将达到11.25亿至11.75亿美元，总收入将扩大至4.50亿至4.75亿美元，远超市场预期的3.195亿美元。此外，公司还预计2026年调整后EBITDA可能超过3亿美元，显示出强劲的盈利潜力。
Ironwood医药表示，通过下调Linzess的目录价格，公司能够应对医疗保健环境的变化并支持患者持续获得治疗，从而推动净销售额的同比增长。这一积极展望显著提振了市场信心，推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.